Evidence map›Paper›PMID 34841914›Full record

ReviewJournal of cutaneous medicine and surgery

Therapeutic Options for the Treatment of Darier's Disease: A Comprehensive Review of the Literature.

Nardin Hanna, Megan Lam, Patrick Fleming, Charles W Lynde

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Darier disease-A review highlighting new insights from the Darier Disease International Task Force.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Qualitative evidence on EQ-5D-5L skin irritation and self-confidence bolt-ons in Darier's disease and Hailey-Hailey disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Combined Abrocitinib and Acitretin Therapy for Darier's Disease: A Case Report.Clinical, cosmetic and investigational dermatology · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Oral Isotretinoin and Its Uses in Dermatology: A Review.Drug design, development and therapy · 2023
    Review
  19. Segmental Darier's disease: A case report.SAGE open medical case reports · 2023
    Article
  20. A Case of Darier's Disease with a Novel Missense Mutation inClinical, cosmetic and investigational dermatology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Nardin Hanna6363 Faculty of Medicine, University of Ottawa, ON, Canada.
Megan Lam12362 Faculty of Medicine, McMaster University, Hamilton, ON, Canada.
Patrick Fleming7938 Division of Dermatology, University of Toronto, ON, Canada.
Charles W Lynde7938 Division of Dermatology, University of Toronto, ON, Canada.
University of Toronto · CAMcMaster University · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Darier's disease (also known as keratosis follicularis or dyskeratosis follicularis) is an autosomal dominant inherited disorder which manifests as hyperkeratotic greasy papules in the first or second decade of life. Aside from symptom management and behavioral modifications to avoid triggers, there are currently no validated treatments for Darier's disease (DD). However, a variety of treatments have been proposed in the literature including retinoids, steroids, vitamin D analogs, photodynamic therapy, and surgical excision. The purpose of this review article is to identify therapeutic options for treating DD and to outline the evidence underlying these interventions. A search was conducted in Medline for English language articles from inception to July 4, 2020. Our search identified a total of 474 nonduplicate studies, which were screened by title and abstract. Of these, 155 full text articles were screened against inclusion/exclusion criteria, and 113 studies were included in our review. We identified Grade B evidence for the following treatments of DD: oral acitretin, oral isotretinoin, systemic Vitamin A, topical tretinoin, topical isotretinoin, topical adapalene gel, topical 5-flououracil, topical calciptriol and tacalcitol (with sunscreen), grenz ray radiation, and x-ray radiation. All other evidence for treatments of DD consisted of case reports or case series, which is considered grade C evidence. Considering the quality and quantity of evidence, clinicians may consider initiating a trial of select topical or oral retinoids first in patients with localized or generalized DD, respectively.

Indexed as

Darier DiseaseAcitretinAdapaleneHumansIsotretinoinSunscreening AgentsAcitretinAdapaleneIsotretinoinSunscreening AgentsDarier’s diseasegenodermatosistreatment

Identifiers

PMID34841914
PMCPMC9125141
OpenAlexW3216507180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.